Fig. 3: Patient responders—daily recordings. | Bone Marrow Transplantation

Fig. 3: Patient responders—daily recordings.

From: Efficacy and safety of multiple doses of NEPA without dexamethasone in preventing nausea and vomiting induced by multiple-day and high-dose chemotherapy in patients with non-Hodgkin’s lymphoma undergoing autologous hematopoietic stem cell transplantation: a phase IIa, multicenter study

Fig. 3

The line graph shows patients’ percentage classified as complete response (no emesis, no rescue medication), complete control (complete response and no more than mild nausea), no emesis, and no rescue therapy monitored for 15 days during and following the BEAM/FEAM regimens. NEPA (N) was given on days 1, 3, and 5. Carmustine (C) or fotemustine (F) was administered on day 1, etoposide (eto) and cytarabine (cyt) from days 2 to 5, and melphalan (M) on day 6.

Back to article page